Sorafenib is an emerging therapeutic option for radioactive iodine (RAI)-refractory differentiated thyroid carcinoma. However, the effects of sorafenib as an adjuvant treatment following surgery or radiation on brain metastases from poorly differentiated thyroid carcinoma (PDTC) have never been reported. A 52-year-old patient underwent total thyroidectomy for follicular thyroid carcinoma. Despite high-dose RAI therapy, a neck mass and lung metastases were developed. PDTC was diagnosed by neck mass removal. During adjuvant external beam radiation therapy (EBRT) to the neck, brain metastases developed. After palliative EBRT for brain metastases, the brain tumor size decreased but lung metastases markedly progressed. Off-label sorafenib was used to treat progressive multiple metastatic lesions. Over five months of sorafenib treatment, the sum of the longest diameters for target lesions was decreased by 45% in brain and 13% in lung. Sorafenib can be considered a new adjuvant therapeutic option for metastatic brain lesions from PDTC after EBRT.
Introduction
Brain metastases occur in approximately 1% of all differentiated thyroid carcinoma (DTC). Despite a low overall incidence and an indolent nature, 4.5-18% of patients with distant metastases from thyroid carcinoma develop brain metastases, resulting in poor mean survival. 1) As only relatively few cases have been described in the literature, management of patients with brain metastases of DTC origin is unclear. 2) Poorly differentiated thyroid carcinoma (PDTC) has a propensity to metastasize distantly (36-85%), most commonly to the lung (14-54%) and bones (18-33%); 3) however, incidence of brain metastases from PDTC has not been previously described. Patients with PDTC often have a high incidence of recurrence despite appropriate treatment. Although there have been multiple publications over the years, controversies regarding optimal management of these patients still exist. 4) Sorafenib is an oral, tyrosine kinase inhibitor of the RAF protein kinase receptor, VEGFR2 and PDGF-β and displays strong anti-angiogenic activity. 5) Because DTC has been well documented to exhibit genetic alterations in the mitogen-activated protein kinase (MAPK) pathway, including BRAF mutations 6) and VEGF overexpression, 7) sorafenib has been proposed as a good candidate therapy for refractory DTC. 8) We treated one patient with rapidly progressive PDTC metastases to brain with radiation therapy and sub- 2.3 cm to 5.4 cm (Fig. 2D ). Although EBRT was recommended for this progressive metastatic brain lesion, she refused further treatment and was transferred to a local palliative and hospice care hospital.
Case Report

Discussion
Our patient had progressive metastatic lesions from PDTC in brain and lungs after surgery and RAI ther- diosurgery or EBRT for effective control of brain metastases from advanced thyroid cancer. 11, 12) We chose EBRT rather than radiosurgery because of the large brain mass size and unstable extra-cranial metastases. Because the progression-free survival of DTC patients treated with EBRT alone for brain metastases is not known, we chose sorafenib treatment for not only progressive lung metastases, but also the brain metastasis in this patient.
Sorafenib is the only tyrosine kinase inhibitor able to target the MAPK pathway and with demonstrated inhibitory activity against VEGFR, PDGFR, and RAF kinases. 5) It is an emerging therapeutic option in the treatment of RAI-refractory advanced or metastatic DTC, especially when there are multiple pulmonary metastases. 13) Since metastatic brain lesions can cause acute life-threatening complications, appropriate management is crucial. However, to the best of our knowledge, there are only two case reports involving treatment of brain metastasis with sorafenib in thyroid cancer patients. One case of a patient with follicular thyroid cancer demonstrated partial response (PR) in the brain metastasis and stable disease (SD) in lung metastatic lesions. 14) Although sorafenib therapy was only given for 16 weeks in another report, no progression occurred in the metastatic brain lesion of a papillary thyroid cancer patient. 15) We chose sorafenib to treat RAI refractory progressive lung metastases. Similar to the response of brain metastases in the previous two reports, 14, 15) radiological examination confirmed good response over five months of sorafenib treatment in not only lung lesions but also brain lesion of our patient. Because the brain accumulation of sorafenib is restricted primarily by ABCG2 (breast cancer resistance protein) and partly by P-gp (P-glycoprotein), 16) this substantial effect on a brain lesion might be due to preceding EBRT. However, considering marked progression (in- antitumor activity for metastatic brain lesion after EBRT.
Unlike brain metastasis, thyroglobulin levels increased during sorafenib treatment presumably due to mediastinal lymphadenopathy progression. Prior studies also showed varying responses to sorafenib treatment in different organs. Lung metastases respond more favorably compared to lymph nodes, 19) bone, or pleural lesions. 20) The pathophysiological mechanism underlying this variable response has been rarely clarified. It remains to be determined whether organspecific responses are derived from different expressions of various VEGFRs or non-VEGF-mediated mechanisms, such as differences in drug concentrations among tissues. 19) Similar to previous reports, 14, 19, 20) sorafenib effectiveness was highest in the brain of our patient, followed by lung and lymph nodes. This suggests that sorafenib treatment be considered a novel adjuvant therapy for massive brain metastasis after EBRT in PDTC patients.
In conclusion, sorafenib can be considered a new adjuvant therapeutic option for metastatic brain lesions 
